FDA rejects Gilead’s cystic fibrosis drug
The US Food and Drug Administration has rejected Gilead Science’s inhaled cystic fibrosis drug aztreonam lysine on the grounds an additional clinical study is required.
Read MoreAuthor: Katrina Megget
Pfizer and Mannkind collaborate on inhaled insulin
Pfizer has made a partnership-of-sorts with fellow inhaled insulin maker Mannkind in a bid to free itself from the last vestiges of its failed Exubera.
Read MoreMore than 30 Ranbaxy drugs banned entry to US
The US Food and Drug Administration has blocked the import of more than 30 Ranbaxy drugs that have been manufactured in two plants in India after concerns were raised about the manufacturing practice.
Read MoreBiovitrum takes on Amgen products
Pharmaceutical company Biovitrum has taken on three of Amgen’s biologics products in a deal worth more than $130 million.
Read MoreEli Lilly and J&J new antipsychotics no more effective in children than older drugs
Shares for Eli Lilly and Johnson & Johnson dropped more than 1% yesterday after a US study found new antipsychotics were no more effective than older conventional ones in treating child and adolescent schizophrenia.
Read More- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
